Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
暂无分享,去创建一个
C. Paweletz | P. Jänne | D. Walt | R. Nishihara | Padric M. Garden | L. Cohen | M. Severgnini | M. Awad | B. Ricciuti | A. Adeni | Alissa Keegan | J. Supplee | Mariano Severgnini
[1] L. Molinero,et al. Abstract CT001: Biomarkers of systemic inflammation associated to reduced clinical activity of atezolizumab monotherapy in patients with metastatic triple negative breast cancer , 2019, Clinical Trials.
[2] J. Wolchok,et al. Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition. , 2019, Journal of Clinical Oncology.
[3] Howard Y. Chang,et al. Clonal replacement of tumor-specific T cells following PD-1 blockade , 2019, Nature Medicine.
[4] D. Walt,et al. Impact of clinical sample handling and processing on ultra-low level measurements of plasma cytokines. , 2019, Clinical biochemistry.
[5] F. Hodi,et al. Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients , 2018, Cell and Tissue Banking.
[6] D. Walt,et al. Long-Term Measurements of Human Inflammatory Cytokines Reveal Complex Baseline Variations between Individuals. , 2017, The American journal of pathology.
[7] G. Freeman,et al. Interleukin‐17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD‐1 Blockade , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] J. Madore,et al. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma , 2017, Clinical Cancer Research.
[9] Jedd D. Wolchok,et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.
[10] Shobha Purushothama,et al. Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serum. , 2016, Journal of immunological methods.
[11] L. Chin,et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.
[12] Martin Jaeger,et al. Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi , 2016, Nature Medicine.
[13] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[14] David R Walt,et al. Single molecule array (Simoa) assay with optimal antibody pairs for cytokine detection in human serum samples. , 2015, The Analyst.
[15] T. Yen,et al. IL-6-stimulated CD11b+CD14+HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus , 2014, Oncotarget.
[16] T. Vyse,et al. C-reactive protein in rheumatology: biology and genetics , 2011, Nature Reviews Rheumatology.
[17] W. Gerald,et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.
[18] J. Stenken,et al. Bioanalytical chemistry of cytokines--a review. , 2015, Analytica chimica acta.